share_log

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target

Benzinga Real-time News ·  Feb 7, 2023 07:43

Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment